Article Text

Download PDFPDF
Therapeutic effect of modified double-dose photodynamic therapy in circumscribed choroidal haemangioma
  1. Hyeong Ju Byeon1,
  2. Ji Hwan Lee1,
  3. Junwon Lee1,
  4. Eun Young Choi1,
  5. Yong Joon Kim1,
  6. Sung Chul Lee2,
  7. Christopher Seungkyu Lee1
  1. 1 Department of Ophthalmology, The Institute of Vision Research, Yonsei University College of Medicine, Seoul, South Korea
  2. 2 Department of Ophthalmology, Konyang University College of Medicine, Daejeon, South Korea
  1. Correspondence to Dr Christopher Seungkyu Lee, Ophthalmology, Yonsei University College of Medicine Department of Ophthalmology, Seodaemun-gu 03722, Seoul, The Republic of Korea; sklee219{at}


Aims To retrospectively compare the therapeutic effect of modified double-dose photodynamic therapy (PDT) with standard-dose PDT in patients with circumscribed choroidal haemangioma (CCH).

Methods Thirty-nine patients with CCH were categorised in two groups by PDT type. The standard-dose group (n=12) was treated with 6 mg/m2 verteporfin and a 689 nm laser for 83 s. The modified double-dose group (n=27) received one vial of verteporfin (15 mg), and the dose was calculated for each patient based on body surface area, then irradiance time was adjusted according to calculated verteporfin dose to achieve a ‘double’-dose effect. Treatment outcomes (foveal centre thickness, subretinal fluid, tumour thickness and diameter) were measured at baseline and 1 year post-treatment; subretinal fluid levels were also measured at 1, 3 and 6 months post-treatment.

Results No differences in baseline characteristics were found between the two groups. The modified double-dose group showed a greater reduction in tumour thickness (45.3% vs 20.6%, p=0.013) and tumour volume (60.0% vs 30.0%, p=0.006) at 1 year post-treatment. Recurred or non-complete resolution patients in the standard-dose group tended to show much increased subretinal fluid than those in the modified double-dose group at 1-year post-treatment.

Conclusion Modified double-dose PDT is an effective and safe protocol for symptomatic CCH management, greater tumour regression and potentially better resolution of subretinal fluid compared with standard PDT.

  • choroid
  • neoplasia
  • retina

Data availability statement

Data are available upon reasonable request.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available upon reasonable request.

View Full Text


  • Contributors All authors participated in the review and editing of the manuscript. JHL, JL, CSL and SL designed this study. HJB, EYC, YJK, CSL and SL collected the data. HJB and CSL analysed and interpreted the data and wrote the manuscript. CSL contributed to the revision of the final manuscript.

  • Funding This research was supported by the Basic Science Research Program through the National Research Foundation of Korea under 2019R1A2C2002393 (CSL).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • Highlights from this issue
    Frank Larkin